Meeting
2024 ASCO Annual Meeting
A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.
Authors
Panpan Zhang
Peking University Cancer Hospital and Institute, Beijing, China
Panpan Zhang , Yanru Qin , Jifang Gong , Yongsheng Wang , Kunyu Yang , Yongsheng Li , Guanghai Dai , Ji Zhu , Sha Sha , Ming Tong , Xuebin Liao , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT05315167
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2590)
DOI
10.1200/JCO.2024.42.16_suppl.2590
Abstract #
2590
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
![EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.](https://d201v5jt9ylckg.cloudfront.net/316/15821/233888/233888_A322_poster_pv.jpg)
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.
First Author: Thomas Lillie
Poster
2023 ASCO Annual Meeting
TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).
First Author: Hossein Borghaei
Poster
2022 ASCO Annual Meeting
Retrospective analysis of the effect of angiotensin receptor blockers and angiotensin converting enzyme inhibitors on the efficacy of anti-PD-1/PD-L1 immunotherapy in patients with advanced cancer.
First Author: Jason Suh
Poster
2022 ASCO Annual Meeting
A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
First Author: Brian Gastman